| abstract |
The invention discloses a Stat3-targeting CRISPR/Cas carrier, a Stat3-HBx double-targeting CRISPR/Cas carrier, and two CRISPR/Cas carriers that repeatedly target HBx, in particular to a Stat3-targeting single-function carrier Plasmid, a Stat3-HBx dual-targeting CRISPR/Cas vector, two CRISPR/Cas vectors repeatedly targeting HBx, and a construction method for the vector. The inventors have proved through experiments that the vector constructed in the invention has a specific targeted therapeutic effect on HBV-related liver cancer cells, and the invention correspondingly protects the above-mentioned gene silencing vector, the construction method of the vector, the vector's double silencing strategy for Stat3 and HBx, and The application of the carrier in the preparation of HBV chronic infection and anti-liver cancer related drugs. |